Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.
Innes AJ, Beattie R, Sergeant R, Damaj G, Foroni L, Marin D, Kanfer E, Mielke S, Milojkovic D, MacDonald D, Pavlu J, Rahemtulla A, Roberts I, Slade D, Bray E, Goldman J, Apperley J, Szydlo R, Dazzi F, Rezvani K.
Innes AJ, et al. Among authors: dazzi f.
Bone Marrow Transplant. 2013 Oct;48(10):1324-8. doi: 10.1038/bmt.2013.69. Epub 2013 May 20.
Bone Marrow Transplant. 2013.
PMID: 23686098